Anti-neoplastic agent thymoquinone induces degradation of [alpha] and [beta] tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Works matching IS 01676997 AND DT 2012 AND VI 30 AND IP 5
Results: 32
1
2
Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1878, doi. 10.1007/s10637-011-9749-7
- By:
- Publication type:
- Article
3
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1972, doi. 10.1007/s10637-011-9759-5
- By:
- Publication type:
- Article
4
Eribulin mesylate in patients with refractory cancers: a Phase I study.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1926, doi. 10.1007/s10637-011-9741-2
- By:
- Publication type:
- Article
5
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1978, doi. 10.1007/s10637-011-9721-6
- By:
- Publication type:
- Article
6
A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1820, doi. 10.1007/s10637-011-9738-x
- By:
- Publication type:
- Article
7
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1813, doi. 10.1007/s10637-011-9734-1
- By:
- Publication type:
- Article
8
The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1849, doi. 10.1007/s10637-011-9746-x
- By:
- Publication type:
- Article
9
First case of posterior reversible encephalopathy syndrome associated with vinflunine.
- Published in:
- 2012
- By:
- Publication type:
- Report
10
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1830, doi. 10.1007/s10637-011-9740-3
- By:
- Publication type:
- Article
11
Cluvenone induces apoptosis via a direct target in mitochondria: a possible mechanism to circumvent chemo-resistance?
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1841, doi. 10.1007/s10637-011-9745-y
- By:
- Publication type:
- Article
12
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
- Published in:
- 2012
- By:
- Publication type:
- Report
13
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1934, doi. 10.1007/s10637-011-9742-1
- By:
- Publication type:
- Article
14
Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1865, doi. 10.1007/s10637-011-9748-8
- By:
- Publication type:
- Article
15
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1908, doi. 10.1007/s10637-011-9756-8
- By:
- Publication type:
- Article
16
Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1950, doi. 10.1007/s10637-011-9751-0
- By:
- Publication type:
- Article
17
A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1887, doi. 10.1007/s10637-011-9752-z
- By:
- Publication type:
- Article
18
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1962, doi. 10.1007/s10637-011-9754-x
- By:
- Publication type:
- Article
19
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1899, doi. 10.1007/s10637-011-9755-9
- By:
- Publication type:
- Article
20
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1942, doi. 10.1007/s10637-011-9747-9
- By:
- Publication type:
- Article
21
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1958, doi. 10.1007/s10637-011-9753-y
- By:
- Publication type:
- Article
22
Continuing pursuit for ideal systemic anticancer radiotherapeutics.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 2050, doi. 10.1007/s10637-011-9758-6
- By:
- Publication type:
- Article
23
Saturable absorption of sorafenib in patients with solid tumors: a population model.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1991, doi. 10.1007/s10637-011-9760-z
- By:
- Publication type:
- Article
24
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1984, doi. 10.1007/s10637-011-9757-7
- By:
- Publication type:
- Article
25
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 2001, doi. 10.1007/s10637-011-9761-y
- By:
- Publication type:
- Article
26
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
- Published in:
- 2012
- By:
- Publication type:
- Report
27
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 2008, doi. 10.1007/s10637-011-9763-9
- By:
- Publication type:
- Article
28
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 2026, doi. 10.1007/s10637-011-9779-1
- By:
- Publication type:
- Article
29
A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 2015, doi. 10.1007/s10637-011-9776-4
- By:
- Publication type:
- Article
30
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 2066, doi. 10.1007/s10637-012-9796-8
- By:
- Publication type:
- Article
31
Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 2080, doi. 10.1007/s10637-012-9797-7
- By:
- Publication type:
- Article
32
The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1917, doi. 10.1007/s10637-012-9859-x
- By:
- Publication type:
- Article